vs
Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and China SXT Pharmaceuticals, Inc. (SXTC). Click either name above to swap in a different company.
ASTRAZENECA PLC is the larger business by last-quarter revenue ($14.5B vs $829.5K, roughly 17428.8× China SXT Pharmaceuticals, Inc.). ASTRAZENECA PLC runs the higher net margin — 16.9% vs -96.8%, a 113.7% gap on every dollar of revenue. On growth, ASTRAZENECA PLC posted the faster year-over-year revenue change (11.7% vs 0.0%).
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the Chinese domestic market. It engages in the research, development, production and distribution of traditional Chinese medicine-based prescription drugs, over-the-counter medications, and nutritional health products, serving both clinical medical institutions and consumer health markets.
AZN vs SXTC — Head-to-Head
Income Statement — Q2 2025 vs Q2 2026
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $829.5K |
| Net Profit | $2.4B | $-802.6K |
| Gross Margin | 82.9% | 16.2% |
| Operating Margin | 24.3% | -76.9% |
| Net Margin | 16.9% | -96.8% |
| Revenue YoY | 11.7% | 0.0% |
| Net Profit YoY | 27.0% | 0.0% |
| EPS (diluted) | $1.57 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $829.5K | ||
| Q2 25 | $14.5B | — | ||
| Q3 24 | — | $829.5K | ||
| Q2 24 | $12.9B | — | ||
| Q3 23 | — | $939.6K | ||
| Q2 23 | $11.4B | — | ||
| Q3 22 | — | $1.2M | ||
| Q2 22 | $10.8B | — |
| Q3 25 | — | $-802.6K | ||
| Q2 25 | $2.4B | — | ||
| Q3 24 | — | $-802.6K | ||
| Q2 24 | $1.9B | — | ||
| Q3 23 | — | $-9.7M | ||
| Q2 23 | $1.8B | — | ||
| Q3 22 | — | $-1.5M | ||
| Q2 22 | $360.0M | — |
| Q3 25 | — | 16.2% | ||
| Q2 25 | 82.9% | — | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | 83.1% | — | ||
| Q3 23 | — | 30.7% | ||
| Q2 23 | 82.8% | — | ||
| Q3 22 | — | 7.4% | ||
| Q2 22 | 72.2% | — |
| Q3 25 | — | -76.9% | ||
| Q2 25 | 24.3% | — | ||
| Q3 24 | — | -76.9% | ||
| Q2 24 | 21.2% | — | ||
| Q3 23 | — | -995.0% | ||
| Q2 23 | 21.5% | — | ||
| Q3 22 | — | -95.2% | ||
| Q2 22 | 5.0% | — |
| Q3 25 | — | -96.8% | ||
| Q2 25 | 16.9% | — | ||
| Q3 24 | — | -96.8% | ||
| Q2 24 | 14.9% | — | ||
| Q3 23 | — | -1032.0% | ||
| Q2 23 | 15.9% | — | ||
| Q3 22 | — | -123.7% | ||
| Q2 22 | 3.3% | — |
| Q3 25 | — | — | ||
| Q2 25 | $1.57 | — | ||
| Q3 24 | — | $-0.25 | ||
| Q2 24 | $1.24 | — | ||
| Q3 23 | — | $-19.34 | ||
| Q2 23 | $1.17 | — | ||
| Q3 22 | — | $-14.61 | ||
| Q2 22 | $0.23 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1B | $18.1M |
| Total DebtLower is stronger | — | $105.0K |
| Stockholders' EquityBook value | $44.8B | $15.4M |
| Total Assets | $112.4B | $21.7M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $18.1M | ||
| Q2 25 | $7.1B | — | ||
| Q3 24 | — | $18.5M | ||
| Q2 24 | $6.9B | — | ||
| Q3 23 | — | $11.5M | ||
| Q2 23 | $5.7B | — | ||
| Q3 22 | — | $3.0M | ||
| Q2 22 | $4.8B | — |
| Q3 25 | — | $105.0K | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $952.3K | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $106.6K | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | $15.4M | ||
| Q2 25 | $44.8B | — | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | $39.6B | — | ||
| Q3 23 | — | $5.1M | ||
| Q2 23 | $37.4B | — | ||
| Q3 22 | — | $14.5M | ||
| Q2 22 | $36.0B | — |
| Q3 25 | — | $21.7M | ||
| Q2 25 | $112.4B | — | ||
| Q3 24 | — | $31.0M | ||
| Q2 24 | $104.3B | — | ||
| Q3 23 | — | $14.6M | ||
| Q2 23 | $96.5B | — | ||
| Q3 22 | — | $22.2M | ||
| Q2 22 | $96.6B | — |
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | — | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | — | ||
| Q3 23 | — | 0.02× | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.4M |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -216.2% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | — | ||
| Q3 23 | — | $-579.6K | ||
| Q2 23 | — | — | ||
| Q3 22 | — | $-549.1K | ||
| Q2 22 | — | — |
| Q3 25 | — | $-1.8M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | -216.2% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
| Q3 25 | — | 4.9% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
